Get the Stockscreener App
2.08
7.77%
0.15
Pre-market:
2.07
-0.01
-0.48%
Vigil Neuroscience Inc stock is traded at $2.08, with a volume of 141.05K.
It is up +7.77% in the last 24 hours and up +22.35% over the past month.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.
See More
Previous Close:
$1.93
Open:
$1.95
24h Volume:
141.05K
Relative Volume:
0.61
Market Cap:
$85.03M
Revenue:
-
Net Income/Loss:
$-78.92M
P/E Ratio:
-1.0097
EPS:
-2.06
Net Cash Flow:
$-72.87M
1W Performance:
+16.85%
1M Performance:
+22.35%
6M Performance:
-44.09%
1Y Performance:
-27.27%
1-Day Range:
$1.9373
$2.10
1-Week Range:
$1.785
$2.10
52-Week Range:
$1.49
$6.06
Vigil Neuroscience Inc Stock (VIGL) Company Profile
Name
Vigil Neuroscience Inc
Sector
Industry
Phone
857-254-4445
Address
100 FORGE ROAD, WATERTOWN
Compare VIGL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VIGL
Vigil Neuroscience Inc
|
2.08 | 85.03M | 0 | -78.92M | -72.87M | -2.06 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Vigil Neuroscience Inc Stock (VIGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-04-24 | Initiated | William Blair | Outperform |
| Dec-19-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Oct-18-23 | Initiated | JMP Securities | Mkt Outperform |
| Mar-31-23 | Initiated | Mizuho | Buy |
| Sep-16-22 | Initiated | Wedbush | Outperform |
| Aug-29-22 | Initiated | H.C. Wainwright | Buy |
| Feb-01-22 | Initiated | Guggenheim | Buy |
| Feb-01-22 | Initiated | Jefferies | Buy |
| Feb-01-22 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-01-22 | Initiated | Stifel | Buy |
View All
Vigil Neuroscience Inc Stock (VIGL) Latest News
Glimpse Group Inc (NASDAQ: VRAR) Down -21.05% This Year: What To Expect Next - Stocks Register
Them too in TREM2: Street keeping AD Vigil - BioWorld Online
Q4 Earnings Estimate for VIGL Issued By William Blair - MarketBeat
Q4 Earnings Forecast for VIGL Issued By William Blair - Defense World
Geode Capital Management LLC Raises Position in Ballard Power Systems Inc. (NASDAQ:BLDP) - Defense World
Geode Capital Management LLC Purchases 66,712 Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL) - Defense World
Vigil Neuroscience Highlights 2024 Corporate Achievements and Upcoming 2025 Milestones - GlobeNewswire
Vigil Neuroscience Lands $40M Sanofi Investment, FDA Signals Path for Accelerated Approval - StockTitan
Vigil Neuroscience stock hits 52-week low at $1.51 By Investing.com - Investing.com South Africa
Vigil Neuroscience stock hits 52-week low at $1.51 - Investing.com
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Sees Significant Decrease in Short Interest - MarketBeat
Vigil Neuroscience director Budd Haeberlein buys $20,520 in shares By Investing.com - Investing.com South Africa
Vigil Neuroscience director Budd Haeberlein buys $20,520 in shares - Investing.com India
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Director Haeberlein Samantha L. Budd Purchases 12,000 Shares - MarketBeat
VIGL stock touches 52-week low at $1.61 amid market challenges - Investing.com India
VIGL stock touches 52-week low at $1.61 amid market challenges By Investing.com - Investing.com South Africa
Vigil neuroscience CEO Ivana Magovcevic-Liebisch acquires $8,350 in stock - Investing.com India
Vigil neuroscience CEO Ivana Magovcevic-Liebisch acquires $8,350 in stock By Investing.com - Investing.com Australia
Vigil Neuroscience stock hits 52-week low at $2.07 - Investing.com India
Vigil Neuroscience (NASDAQ:VIGL) and ProKidney (NASDAQ:PROK) Head-To-Head Contrast - Defense World
Vigil Neuroscience initiated with an Outperform at William Blair - MSN
FY2024 Earnings Estimate for VIGL Issued By William Blair - MarketBeat
FY2024 Earnings Forecast for VIGL Issued By William Blair - Defense World
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vigil Neuroscience, Inc. (NASDAQ: VIGL) - The Eastern Progress Online
William Blair Initiates Coverage on Vigil Neuroscience (NASDAQ:VIGL) - Defense World
Vigil neuroscience CEO Ivana Magovcevic-Liebisch buys $11,700 in stock By Investing.com - Investing.com Australia
Vigil neuroscience CEO Ivana Magovcevic-Liebisch buys $11,700 in stock - Investing.com
William Blair Initiates Coverage of Vigil Neuroscience (VIGL) with Outperform Recommendation - MSN
William Blair initiates Vigil Neuroscience with Outperform By Investing.com - Investing.com Nigeria
William Blair initiates Vigil Neuroscience with Outperform - Investing.com
Vigil Neuroscience shares rated Outperform by William Blair, advancing in Alzheimer's treatment - Investing.com Nigeria
Vigil Neuroscience: Down On A Competitor's Failure (NASDAQ:VIGL) - Seeking Alpha
Contrasting Vigil Neuroscience (NASDAQ:VIGL) and Surrozen (NASDAQ:SRZN) - Defense World
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Update - MarketBeat
JMP Securities Reiterates Market Outperform Rating for Vigil Neuroscience (NASDAQ:VIGL) - Defense World
Guggenheim maintains Buy on Vigil Neuroscience stock post-Alector trial By Investing.com - Investing.com Canada
Vigil Neuroscience stock hits 52-week low at $2.45 - Investing.com India
Vigil Neuroscience stock hits 52-week low at $2.45 By Investing.com - Investing.com UK
Guggenheim maintains Buy on Vigil Neuroscience stock post-Alector trial - Investing.com
Vigil Neuroscience's (VIGL) Market Outperform Rating Reiterated at JMP Securities - MarketBeat
Citadel Advisors LLC Adjusts Position in Vigil Neuroscience Inc - GuruFocus.com
Vigil Neuroscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Deep Track Capital, LP Increases Stake in Vigil Neuroscience Inc - GuruFocus.com
Vigil Neuroscience to Present at Upcoming Investor Conferences - GlobeNewswire
Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business UpdateOn November 7, 2024, Vigil Neuroscience, Inc. (NASDAQ: VIGL) released its financial results for the third quarter ended September 30, 2024. The company, dedic - Defense World
Vigil Neuroscience’s (VIGL) “Buy” Rating Reiterated at HC Wainwright - Defense World
Vigil Neuroscience (NASDAQ:VIGL) Price Target Raised to $24.00 - Defense World
Vigil Neuroscience Inc Stock (VIGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):